Wed, Jul 23, 2014, 7:26 AM EDT - U.S. Markets open in 2 hrs 4 mins

Recent

% | $
Click the to save as a favorite.

Amarin Corporation plc Message Board

  • mtdsus mtdsus Aug 23, 2012 2:51 PM Flag

    Why BUY OUT failed in May,2011?

    There was an attempt to buy Amarin in April,2011 after Marine 3 trial results were public.Sun Times reported it and Amarin conformed it in June,2011 to Bloomberg reporter. on 6/10/2011.
    It was simply PRICE. Joe wanted 30$ -bidders were offering close to 15$/share.
    During last 15 months--Amarin has gotten great results for Anchor 3 trials for 200-500mg.population.
    Their patent position has improved--protection thru 2030 looks solid.(Yes,Generics will create trouble if NCE for 5 years is NOT granted)-but patents will have to be enforced by Amarin.
    NOW--8 analysts from MKM(21.50) to Jeffries (28$) are all rating it Strong Buy or BUY.
    As happened with Warner Lambert in 1997--when Merck and Pfizer were reluctant to pay big money(as results with patients were great--but CONSUMERS WILLING to switch from ZOCOR to LIPITOR was unknown).When Pfizer achieved 18% market share for Lipitor--every one was SHOCKED.
    Warner Lambert Value tripled in 1999--when bidding took place.

    SAME COULD HAPPEN in 2012--RIGHT PRICE could keep Amarin and PFIZER apart,but ultimately--Merck or Pfizer will buy AMARIN in 2013 .

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • todhale@rocketmail.com todhale Aug 23, 2012 3:20 PM Flag

      Do you think that was a lessoned learned and they'll pony up $28-31 soon? I still cannot shake the thought that reduce-it/combo potential is a smart gamble for BP down the road and they would want to lock up amrn now. My magic 8-ball is refusing to answer me anymore when I ask about amrn!

      Sentiment: Strong Buy

 
AMRN
1.58+0.06(+3.95%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.